Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 8/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105105 | 1.00 | S1PR1 (0.53) | S1PR1S1PR2S1PR3LPAR2ADRB3 | |
| SCHEMBL9101465 | 0.87 | S1PR1 (0.53) | S1PR1S1PR3ADRB3ADRB2ADRB1 | |
| SCHEMBL9101462 | 0.87 | S1PR1 (0.53) | S1PR1S1PR3ADRB3ADRB2ADRB1 | |
| SCHEMBL9099006 | 0.86 | S1PR1 (0.59) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL9098994 | 0.86 | S1PR1 (0.59) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL16174933 | 0.86 | S1PR1 (0.40) | S1PR1ADRB3ADRB2ADRB1LMNA | |
| SCHEMBL9102274 | 0.84 | S1PR1 (0.58) | S1PR1S1PR2S1PR3LPAR2ADRB3 | |
| SCHEMBL9102263 | 0.84 | S1PR1 (0.58) | S1PR1S1PR2S1PR3LPAR2ADRB3 | |
| SCHEMBL9101785 | 0.82 | S1PR1 (0.52) | S1PR1S1PR2S1PR3LPAR2ADRB3 | |
| SCHEMBL9101777 | 0.82 | S1PR1 (0.52) | S1PR1S1PR2S1PR3LPAR2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-08-20 | — | — | US | claimed |
| EP-2646114-B1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-22 | — | — | EP | claimed |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8609636-B2 | Oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-17 | — | — | US | claimed |
| EP-2646114-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| WO-2012074782-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142642-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2646114-B1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8609636-B2 | Oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2646114-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012074782-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142642-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142642-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR2 3/4885S1PR3 2/4885 |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR2 3/4885S1PR3 2/4885 |
| US-20120142642-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR2 3/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.